Leidos invests $10 million in AI disease detection with University of Pittsburgh
Leidos (NYSE: LDOS) has announced a $10 million investment in a five-year collaboration with the University of Pittsburgh's Computational Pathology and AI Center of Excellence (CPACE). The partnership aims to accelerate the development of AI-powered tools for disease detection and management, particularly focusing on heart disease and cancer.
The collaboration will establish a world-class research hub through CPACE's Digital Pathology Research Center, develop digital healthcare solutions, and accelerate global impact through AI-powered pathology solutions across public and private healthcare sectors. Key objectives include exploring new imaging methods, advanced scanning technologies, and improved medical image analysis techniques.
The initiative also emphasizes workforce development through educational programs, industry-focused best practices, annual symposiums, and internship opportunities. Leidos brings over 25 years of experience operating the National Cancer Institute's Frederick National Laboratory for Cancer Research and two decades of AI application expertise in healthcare, national security, and energy sectors.
Leidos (NYSE: LDOS) ha annunciato un investimento di 10 milioni di dollari in una collaborazione quinquennale con il Computational Pathology and AI Center of Excellence (CPACE) dell'Università di Pittsburgh. La partnership mira ad accelerare lo sviluppo di strumenti basati sull'intelligenza artificiale per la rilevazione e la gestione delle malattie, con un focus particolare sulle malattie cardiache e il cancro.
La collaborazione creerà un centro di ricerca di livello mondiale attraverso il Digital Pathology Research Center di CPACE, svilupperà soluzioni digitali per la sanità e amplificherà l'impatto globale tramite soluzioni di patologia potenziate dall'IA nei settori sanitari pubblici e privati. Gli obiettivi principali includono l'esplorazione di nuovi metodi di imaging, tecnologie di scansione avanzate e tecniche migliorate di analisi delle immagini mediche.
L'iniziativa pone anche l'accento sullo sviluppo delle competenze attraverso programmi educativi, best practice orientate all'industria, simposi annuali e opportunità di tirocinio. Leidos vanta oltre 25 anni di esperienza nella gestione del Frederick National Laboratory for Cancer Research del National Cancer Institute e due decenni di competenze nell'applicazione dell'IA nei settori della sanità, della sicurezza nazionale e dell'energia.
Leidos (NYSE: LDOS) ha anunciado una inversión de 10 millones de dólares en una colaboración de cinco años con el Centro de Excelencia en Patología Computacional e IA (CPACE) de la Universidad de Pittsburgh. La asociación tiene como objetivo acelerar el desarrollo de herramientas impulsadas por IA para la detección y gestión de enfermedades, con un enfoque particular en enfermedades cardíacas y cáncer.
La colaboración establecerá un centro de investigación de clase mundial a través del Centro de Investigación en Patología Digital de CPACE, desarrollará soluciones digitales de salud y acelerará el impacto global mediante soluciones de patología impulsadas por IA en los sectores de salud pública y privada. Los objetivos clave incluyen explorar nuevos métodos de imagen, tecnologías avanzadas de escaneo y técnicas mejoradas de análisis de imágenes médicas.
La iniciativa también enfatiza el desarrollo de la fuerza laboral mediante programas educativos, mejores prácticas enfocadas en la industria, simposios anuales y oportunidades de pasantías. Leidos aporta más de 25 años de experiencia operando el Laboratorio Nacional Frederick para la Investigación del Cáncer del Instituto Nacional del Cáncer y dos décadas de experiencia en la aplicación de IA en los sectores de salud, seguridad nacional y energía.
Leidos (NYSE: LDOS)는 피츠버그 대학교의 계산병리 및 인공지능 우수센터(CPACE)와 5년간 1,000만 달러 규모의 협력 투자를 발표했습니다. 이번 파트너십은 특히 심장질환과 암에 중점을 두어 인공지능 기반 질병 탐지 및 관리 도구 개발을 가속화하는 것을 목표로 합니다.
이번 협력은 CPACE의 디지털 병리 연구 센터를 통해 세계적 수준의 연구 허브를 구축하고, 디지털 헬스케어 솔루션을 개발하며, 공공 및 민간 의료 분야 전반에 걸쳐 인공지능 기반 병리 솔루션을 통해 글로벌 영향력을 확대할 예정입니다. 주요 목표는 새로운 영상 기법, 첨단 스캐닝 기술, 개선된 의료 영상 분석 기법을 탐구하는 것입니다.
이 이니셔티브는 교육 프로그램, 산업 맞춤형 우수 사례, 연례 심포지엄, 인턴십 기회를 통한 인력 개발도 강조합니다. Leidos는 국립암연구소의 프레더릭 국립암연구소 운영 경험 25년 이상과 의료, 국가 안보, 에너지 분야에서 인공지능 적용 경험 20년 이상을 보유하고 있습니다.
Leidos (NYSE : LDOS) a annoncé un investissement de 10 millions de dollars dans une collaboration de cinq ans avec le Computational Pathology and AI Center of Excellence (CPACE) de l'Université de Pittsburgh. Ce partenariat vise à accélérer le développement d'outils basés sur l'intelligence artificielle pour la détection et la gestion des maladies, en se concentrant particulièrement sur les maladies cardiaques et le cancer.
La collaboration établira un centre de recherche de classe mondiale via le Digital Pathology Research Center de CPACE, développera des solutions numériques pour la santé et accélérera l'impact mondial grâce à des solutions de pathologie assistées par IA dans les secteurs de la santé publics et privés. Les objectifs clés incluent l'exploration de nouvelles méthodes d'imagerie, des technologies de numérisation avancées et des techniques améliorées d'analyse d'images médicales.
L'initiative met également l'accent sur le développement des compétences à travers des programmes éducatifs, des bonnes pratiques orientées industrie, des symposiums annuels et des opportunités de stages. Leidos apporte plus de 25 ans d'expérience dans la gestion du Frederick National Laboratory for Cancer Research du National Cancer Institute et deux décennies d'expertise dans l'application de l'IA dans les secteurs de la santé, de la sécurité nationale et de l'énergie.
Leidos (NYSE: LDOS) hat eine Investition von 10 Millionen US-Dollar in eine fünfjährige Zusammenarbeit mit dem Computational Pathology and AI Center of Excellence (CPACE) der Universität Pittsburgh angekündigt. Die Partnerschaft zielt darauf ab, die Entwicklung KI-gestützter Werkzeuge zur Krankheitserkennung und -behandlung zu beschleunigen, mit besonderem Fokus auf Herzkrankheiten und Krebs.
Die Zusammenarbeit wird ein erstklassiges Forschungszentrum durch CPACE's Digital Pathology Research Center etablieren, digitale Gesundheitslösungen entwickeln und den globalen Einfluss durch KI-gestützte Pathologielösungen im öffentlichen und privaten Gesundheitswesen beschleunigen. Wichtige Ziele sind die Erforschung neuer Bildgebungsmethoden, fortschrittlicher Scantechnologien und verbesserter medizinischer Bildanalyseverfahren.
Die Initiative legt zudem Wert auf die Entwicklung der Fachkräfte durch Bildungsprogramme, branchenorientierte Best Practices, jährliche Symposien und Praktikumsmöglichkeiten. Leidos bringt über 25 Jahre Erfahrung im Betrieb des Frederick National Laboratory for Cancer Research des National Cancer Institute sowie zwei Jahrzehnte Expertise in der Anwendung von KI in den Bereichen Gesundheitswesen, nationale Sicherheit und Energie mit.
- Strategic $10M investment in AI healthcare technology development
- Potential commercialization opportunities in public and private healthcare sectors
- Leverages existing expertise from 25+ years of cancer research laboratory operations
- Expansion into growing AI-powered diagnostic solutions market
- Significant upfront investment with long-term ROI timeline
- Research and development outcomes uncertainty
- Regulatory approval requirements may delay commercialization
Insights
Leidos' $10M AI healthcare partnership with University of Pittsburgh enhances their competitive position in the growing healthcare AI market.
Leidos'
While the
The collaboration includes three valuable components beyond monetary investment:
- Development of commercialization pathways for AI-powered diagnostic technologies
- Creation of a talent pipeline through educational programs and internships
- Expansion of Leidos' capabilities to serve both government (including veterans) and commercial healthcare sectors
This initiative aligns with healthcare industry's increasing adoption of AI for diagnostic efficiency and positions Leidos at the intersection of government contracting and healthcare innovation. By leveraging university research capabilities, Leidos gains R&D leverage while developing intellectual property that could enhance their competitiveness for larger healthcare contracts and potentially open new revenue streams beyond their core government business.
This partnership strengthens Leidos' position for government healthcare contracts by developing AI capabilities that align with federal healthcare modernization priorities.
This University of Pittsburgh collaboration strategically positions Leidos to strengthen its competitive advantage in the federal health technology contracting space. The company's decision to invest in AI-driven healthcare aligns perfectly with their extensive government contracting portfolio, particularly their long-standing relationship managing the National Cancer Institute's Frederick National Laboratory.
The specific mention of improving healthcare for veterans is particularly noteworthy. Federal agencies like the VA and Department of Defense are increasingly prioritizing AI-enabled healthcare solutions to improve efficiency and quality of care. By developing validated AI diagnostic tools with proper regulatory compliance (explicitly mentioned in the article), Leidos is positioning itself to capture significant government contracts in this high-growth sector.
This partnership provides Leidos with three competitive advantages in the federal contracting space:
- Academic validation necessary for government adoption of AI healthcare technologies
- Regulatory pathway expertise critical for federal healthcare implementation
- Development of specialized workforce familiar with both AI technology and government requirements
The collaboration's emphasis on underserved communities, including veterans, directly aligns with federal healthcare priorities and funding streams. This positions Leidos to potentially leverage this
The initial focus of the five-year collaboration will be developing AI-powered tools for quicker detection of diseases, such as heart disease and cancer, reducing diagnostic turnaround times, and enabling earlier, more effective care management.
"Our investment is aimed at using the transformative power of artificial intelligence to speed detection, diagnosis and treatment of diseases that affect millions of people annually," said Leidos CEO Tom Bell. "These efforts will also focus on developing future health care specialists, and expanding the care that's available to underserved communities, including our veterans."
For more than 25 years, Leidos has operated the National Cancer Institute's Frederick National Laboratory for Cancer Research, supporting progress in the fight against cancer. The company also brings more than two decades of experience applying AI to important areas like health care, national security, and energy, and helps improve care for military families and veterans by strengthening delivery, access, and continuity of care.
Key objectives of the Leidos-University of
- Establishing a World-Class Research Hub: University of
Pittsburgh will enhance CPACE by continuing development of its state-of-the-art Digital Pathology Research Center. These facilities will drive pioneering research in digital pathology and AI-driven diagnostics. - Developing Digital Health Care Solutions: Advancing AI-powered technologies will cement the University of
Pittsburgh's leadership in digital pathology and enable Leidos to develop innovative solutions designed to support digital health and diagnostics. - Accelerating Global Impact: Leidos plans to leverage the collaboration to deploy AI-powered digital pathology solutions across public and private health care sectors with the goal of leading the commercialization of innovative health care technologies.
"The University of
Through this multi-year collaboration, Leidos and the University of
- Research & Technology Development: Joint research projects will explore new imaging methods, advanced scanning technologies to analyze tissue samples, and improved techniques for analyzing medical images with precision.
- Workforce Development & Education: The initiative will cultivate the next generation of health care and AI innovators through comprehensive educational programs, including industry-focused best practices, annual symposiums, and hands-on internship opportunities where students will collaborate directly with Leidos experts.
"We want these tools to impact as many people as possible globally. Leidos can help get them into many more hands, ensuring that they are validated properly and get through the right regulatory frameworks," said Hooman Rashidi, executive director of CPACE and associate dean of AI in medicine at the University of Pittsburgh School of Medicine.
By merging academic excellence with technological innovation, the collaboration is poised to redefine the future of health care delivery and disease management.
"This relationship with Leidos serves as a catalyst to expedite our mission. Industry partnership will help broaden the impact of Pitt's innovation," said Liron Pantanowitz, Dr. Maud L. Menten Professor and chair of the Department of Pathology at the University of Pittsburgh School of Medicine.
About Leidos
Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Partnering with government agencies, Leidos helps improve health outcomes across the
About University of
As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition.
Certain statements in this announcement constitute "forward-looking statements" within the meaning of the rules and regulations of the
Media Contacts
Leidos:
Brandon Ver Velde
(571) 526-6257
brandon.p.vervelde@leidos.com
University of
Nick
nfrance@pitt.edu
View original content to download multimedia:https://www.prnewswire.com/news-releases/leidos-invests-10-million-in-ai-disease-detection-with-university-of-pittsburgh-302432439.html
SOURCE Leidos Holdings, Inc.
FAQ
What is the value and duration of Leidos' (LDOS) investment in the University of Pittsburgh's AI initiative?
What are the main objectives of the Leidos-University of Pittsburgh collaboration in 2025?
How will the Leidos (LDOS) investment in AI disease detection benefit healthcare?
What experience does Leidos bring to the University of Pittsburgh partnership?
